Chest pain sends more than five million Americans to a hospital emergency room each year. Healthcare workers use imaging techniques and electrocardiograms (ECGs) – which translate the heart’s electrical activity into line tracings on paper – to help determine quickly if the pain indicates heart trouble.
The problem, however, is that standard ECG only graphs the low-frequency band, which doesn’t give the full picture.
Now there’s an advanced and low-cost tool available for more accurate ECG results in patients at rest. Israel’s BSP has received US Food and Drug Administration (FDA) approval to market and sell its HyperQ Rest System to aid in the diagnosis of patients with chest pain in the emergency room.
BSP chief executive officer Tamir Ben-David tells ISRAEL21c that the company’s intellectual property is based on research showing that the heart’s electrical signals in high frequency are useful in diagnosing heart ischemia (inadequate blood supply to the heart) and can identify up to 80 percent more patients with ischemia when used with a traditional stress ECG.
“BSP wanted to evaluate how the high-frequency component, a biological signal, has a different frequency domain,” says Ben-David, a physicist with business experience in implantable medical device platforms.
More...
